Precision medicine stands to deeply transform healthcare by tailoring care precisely to the individual, taking into account such personal characteristics as ethnicity, local environmental exposures, immunization history, and more. This exacting approach to care will leverage big data, genomics, and increasing interoperability to help clinicians identify the most appropriate, cost-effective treatments, and even spot previously undetected causes of disease.

This report will define precision medicine (explaining how it differs from population-based medicine), discuss real-world benefits of precision medicine, and look at how greater biological insight (the human genome) and novel technologies can help overcome the financial, data management, and interoperability barriers to fully realizing the promise of precision medicine.

**Precision Medicine Moves Care from Population-Based Protocols to Truly Individualized Medicine**

President Obama announced the Precision Medicine Initiative in his 2015 State of the Union address. Under the initiative, medical care would transition from a one-size-fits-all approach to an individualized approach, in which data on each patient’s genomic makeup, environment, and lifestyle (the exposome) helps medical professionals tailor treatment and prevention strategies. To achieve the Precision Medicine Initiative mission statement, “to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care,” researchers and clinicians need vast and varied amounts of data and the technology to ensure that data is widely accessible and usable.
The Population–Personalization–Precision Continuum

The healthcare industry often uses the term “personalized medicine” to describe a population-based approach to care; personalized medicine is less individualized than precision medicine. Personalized medicine is a one-size-fits-all approach to healthcare, in which clinicians choose treatment according to protocols based on cohorts of patients that may not represent all individuals.

In reality, healthcare is progressing along a continuum from population health to personalized medicine to precision medicine. The goal at the precision level (to improve health and treat disease by tailoring treatment to individuals) picks up where population and personalized approaches leave off.

For example, a health system will treat a 60-year-old woman with diabetes using the protocol shown effective for 60-year-old women with diabetes. This population-level guideline, however, doesn’t take into account other medical and lifestyle factors affecting the patient’s health and ability to follow the treatment plan, such as comorbidities and physical limitations or environmental factors that make self-care or accessing medication and supplies difficult. Likewise, the cohort population used to develop the treatment guideline may not be consistent with the patient’s ethnicity and environment.

In more specific, real-life examples, a non-precision approach to care can mean insurance companies base medication coverage on population-based guidelines, rather than what’s appropriate for a specific patient, or that clinicians choose inappropriate treatments with dangerous risk side effects:

- When a Korean woman underwent treatment for estrogen-positive stage 3 breast cancer, her care team prescribed Lupron® (leuprolide) to stop estrogen production and prevent recurrence. The insurance company, however, said they wouldn’t pay for the prescribed dosage of 22 milligrams per quarter because a 28-year-old study had shown that 11 milligrams was effective. Not only was the study outdated, its cohort was 13 Norwegian women—a population with a very different genetic makeup to the Korean woman in question. In contrast, a more insightful precision medicine approach would give the insurance company the clinical background to understand why a particular protocol was chosen for an individual patient.

- When a man with multiple sclerosis participated in multiple clinical trials of the latest bio-engineered drugs for the disease, he learned that when a drug maker says a medication is effective for multiple sclerosis, it’s effective for maybe 25 percent of patients—and no one knows who that 25 percent may be. Additionally, in this man’s experience, the drug was often worse than the disease in terms of fatigue, stiffness, pain, and more severe side effects. With precision medicine’s big-data-driven perspective (including medical history, environmental exposures, and genomic analysis), patients like this man could learn which drugs might be effective and which were likely to cause more harm than good.

As appealing as the promise of individually tailored treatments for each patient is, researchers and innovators face significant challenges in achieving precision medicine. With the support of
several prominent healthcare trends, however, the champions of precision medicine will have
the capability to access and manage the vast amount of data needed to drive individualized
care while improving outcomes and lowering costs.

Precision Medicine: Four Trends Make It Possible

Given four notable trends in healthcare, precision medicine stands to grow and transform the way
patients experience care over the next few years:

1. Decision support methods harness the power of the human genome.
3. Reimbursement methods incentivize health systems to keep patients well.
4. Emerging tools enable more data, more interoperability.

#1: Decision Support Methods Harness the Power of the Human Genome

Precision medicine uses genomic information (in addition to medical histories and patients’ self-
reported experiences) to determine the best care for each individual. The National Human
Genome Research Institute (NHGRI) defines genomic medicine as “an emerging medical
discipline that involves using genomic information about an individual as part of their clinical
care (e.g., for diagnostic or therapeutic decision-making) and the other implications of that
clinical use” A human genome contains an individual’s complete set of DNA, which includes all
genes.

Francis Collins, the former director of NHGRI, described the genome as a book with multiple
uses and “a transformative textbook of medicine, with insights that will give healthcare
providers immense new powers to treat, prevent, and cure disease.” In the care setting, these
insights can help clinicians make treatment and prevention decisions that target an
individual’s actual risks and circumstances, versus following population-based guidelines that
may not serve that patient.

For example, according to a 2009 study published in The New England Journal of Medicine, for
men over 50 in the general population prostate specific antigen (PSA) testing hasn’t significantly
reduced morbidity and mortality over the past decade. While annual PSA testing may not be
appropriate for all men, some men may be at high risk for death from prostate cancer, which
 genomic profiling can indicate. Regardless of population-based guidelines, these high-risk men
may still benefit from annual prostate testing (by catching prostate cancer in its early, most
treatable stages).

#2: Healthcare Leverages Big Data Analytics and Machine Learning Technologies

In precision medicine, researchers and clinicians who aggregate the most genomes,
exposomes, and rich patient clinical histories with advanced machine learning technologies, will
have the best outcomes. However, tailoring care to more effectively treat and prevent
diseases, requires significantly more robust data than clinicians and researchers currently
collect and hold in the EHR. Specifically missing is patient-generated data. They’ll also
need analytical tools (e.g., machine learning) that can turn this vast amount of complex data
into insights about care.
The previous prostate risk example shows how precision medicine requires machine learning (versus generalized analytics), as genomic information makes disease identification less deterministic. Instead of looking at columns and rows to identify disease, users will have to work with probabilities. The genomic factor, with the support of machine learning analysis to see beyond traditional data sets, gives a more specific picture of an individual’s health. For example, if the prevalence of prostate cancer is 5 percent, and an individual has an increased risk of 50 percent, his increased risk is 7.5 percent. Due to this increased risk, this patient should receive a PSA test, although he generally falls into the population-based cohort that would preclude testing at his age.

As evidence of the current value of genomics, major healthcare organizations are acquiring startups in the field. Recently, Centene, the largest Medicaid processor in our country, acquired a clinical and genomics data analytics business, company Interpreta. With Interpreta’s genomic information, Centene, gains the necessary insight to deliver precise care at the right time and at the right cost for the under-insured and uninsured.

**Enhanced interoperability supports the data-sharing demands of precision medicine.**

With the more complex nature of genomic data (compared with relatively simple data points, such as lists and lab results) clinicians need more sophisticated technologies to access data. Existing EHRs are limited in their data-sharing abilities (and their genomic content), but new ways of exchanging data, such as FHIR-based APIs that can ingest medical records from major EHRs, will enable the interoperability precision medicine requires.

With FHIR now in every iPhone and the growing availability of mobile apps and wearable devices that can detect everything from blood sugar levels to sleep patterns, patients are increasingly transmitting data from the home. This level of interoperability adds to the data set by enabling patient-reported outcomes and subjective information (e.g., mood, pain levels, etc.).

With this clear demand for greater data sharing, the Argonaut Project is addressing challenges to modern, open interoperability standards. This impacts precision medicine as data-sharing and interoperability standards between EHR vendors must expand to allow for individually tailored care. The Argonaut project creates an ecosystem of apps that allow EHR vendors to connect with the project’s set of clinical decision-support tools. All major EHR vendors have committed to adopting the Argonaut standards in 2018.

For example, Interpreta, a cloud-hosted, genomics-interpretation service, works with the Argonaut Project’s standards to help provide patients with accurate and timely care (a decision-support service). A health system EHR can contact Interpreta, which evaluates a patient’s chart against the genomic information in its database and develops a treatment recommendation. In a mature precision-medicine environment, these sorts of decision-support tools will be plug-ins that will run in the background on the EHR. Frontline clinicians won’t even be aware of them.
Mobile health apps bridge the gap between home and the healthcare setting.

**BIDMC@Home** is Beth Israel Deaconess Medical Center’s home-monitoring app (Figure 1) that translates between the data a patient collects at home and the clinician’s office, ensuring that information is accurate. BIDMC@Home uses a care plan creator, a tool within the EHR, to develop a daily care plan (including medications, diet, and activity) for each patient based on her health record and delivers that plan to the patient’s phone.

![BIDMC@Home home monitoring app](image)

**Figure 1: The BIDMC@Home home monitoring app**

**#3: Reimbursement Methods Incentivize Health Systems to Keep Patients Well**

As payment-reimbursement models change from fee-for-service to value-based purchasing, precision medicine stands to be a cost-effective solution. Precision approaches aim to cut down on the redundant and unnecessary testing and avoidable hospital admissions, which drive up cost in a value-based setting.

This shift in reimbursement incentivizes health systems to take the types of actions that create the data precision medicine requires, such as putting bathroom scales in the home of patients with congestive heart failure and engaging visiting nurses, home care, telecare, and telemedicine. These interventions generate more data that helps keep individuals healthy and avoids hospitalization or unnecessary imaging, while building on the data loop that drives precision medicine.
Precision medicine helps close the health data loop by sustaining a continuous cycle of feedback. The loop builds a comprehensive health knowledge base of clinical, self-reported, and biometric data (e.g., heart rates, activity levels, and sleeping habits) that helps clinicians and researchers better treat and prevent disease.

But to close this feedback loop of health data, simplifying operations—which in turn frees up resources to analyze the influx of new patient data—requires that the medical industry incorporate new skillsets. Stanford’s Department of Biomedical Data Science (DBDS) is trying to do just that: teaching doctors and researchers how to utilize medical data in practical ways.

**Emerging Tools Enable More Data, More Interoperability**

According to the 2017 Gartner Hype Cycle for Emerging Technologies (Figure 2), blockchain is among the technologies forecasted to reach the peak of inflated expectation in 2018. But for precision medicine, blockchain may have real potential.

Because machine learning techniques are more powerful with bigger training sets and more data, precision medicine needs methods to get more data. Some researchers are proposing using blockchain to pay patients for their clinical data, internet-of-things data, or genomic data. The contribution, which could be anonymous, contributes to the larger body of health and genomic data needed for precision medicine.
Blockchain also functions as a good auditing tool and may have a role in care coordination. Today, about 25 percent of patients seek care outside of their network. Even with advanced interoperability, it’s difficult to track all the places an individual receives care and where his records are.

Healthcare blockchain users, however, have to take precautions when it comes to patient privacy. As a public ledger, blockchain discloses where a patient has sought treatment and, in doing so, discloses a possible clinical condition (e.g., if a patient has a record at an alcohol treatment facility, it suggests an alcohol abuse problem). A blockchain pilot program with Harvard and MIT is testing a consent management contract that protects privacy along with data integrity.

**Precisions Medicine Leverages Big Data, Analytics, and Technology for Truly Individualized Care**

With this timely convergence of expanding genomic data, novel big data and machine learning technologies, new reimbursement methods, and potential tools (e.g., blockchain) on the horizon, precision medicine will have the infrastructure to realize its promise of providing exactly the care a patient might—or might not—need according to her personal genomic make-up and health history. To be a part of the transformation to truly individualized care, health systems will need to harness the potential of big data and machine learning capabilities to expand their data access and interoperability beyond traditional EHRs (including integrating genomic data), continue to adapt to value-based reimbursement, and stay aware of emerging tools that can individualize care and further the mission of precision medicine.

**About the Author**

John D. Halamka, MD, MS, is a Professor of Medicine at Harvard Medical School, Chief Information Officer of Beth Israel Deaconess Medical Center, Chairman of the New England Healthcare Exchange Network (NEHEN), co-Chair of the national HIT Standards Committee, co-Chair of the Massachusetts HIT Advisory Committee and a practicing Emergency Physician. As Chief Information Officer of Beth Israel Deaconess Medical Center, he is responsible for all clinical, financial, administrative and academic information technology serving 3000 doctors, 14000 employees and two million patients. As Chairman of NEHEN he oversees clinical and administrative data exchange in Eastern Massachusetts. As co-Chair of the HIT Standards Committee he facilitates the process of electronic standards harmonization among stakeholders nationwide. As co-Chair of the Massachusetts HIT Advisory Committee, he engages the stakeholders of the Commonwealth to guide the development of a statewide health information exchange.